Javed N Agrewala

Javed N Agrewala

Chief Scientist, Immunology Laboratory, Institute of Microbial Technology,
Sector 39A, Chandigarh 160 036,
Email: javed@imtech.res.in, jagrewala@gmail.com

Javed N Agrewala, IMTECH, Chandigarh, elected to Fellowship in 2015. Agrewala’s current research interest is in microbial pathogenesis in diseases like tuberculosis where a coordinated cross-talk between macrophages and T cells is essential for protection. His group is addressing questions that would provide insights not only into mechanisms of pathogenesis but may also suggest targets for therapeutic intervention. He is a recipient of the Shanti Swarup Bhatnagar Award.

Session 1C - Inaugural Lecture

Caerulomycin A suppresses arthritis symptoms by expanding regulatory T cells

Caerulomycin A is a bipyridyl compound produced by actinomycetes and is known to exhibit antifungal and antibiotic properties. The role of Caerulomycin A as an immunosuppressive agent in alleviating the arthritis symptoms by generating regulatory T cells (Tregs) was exploited in our studies. It was observed that Caerulomycin A substantially augmented the percentage of Tregs. Further, it suppressed the number of Th1 cells and Th17 cells. Furthermore, the mechanism was established and that Caerulomycin A interfered with IFN-γ induced STAT1 signalling by augmenting SOCS1 expression was observed. An increase in the TGF-β mediated Smad3 activity was also noted. Caerulomycin A rescued Tregs from IFN-γ induced inhibition. In essence, our results suggest a novel role of Caerulomycin A in the formation of Tregs. This finding proposes that Caerulomycin A has sufficient potential to be considered as a future drug to treat arthritis.

© 2016 Indian Academy of Sciences, Bengaluru.